Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$2.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Soleno Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Soleno Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-4.8%

Buyback Yield

Total Shareholder Yield-4.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

Recent updates

Seeking Alpha • Mar 21

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory

Summary Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic condition with no current FDA-approved treatments. Despite positive analyst ratings and a strong cash position, insider selling and competition from companies like Aardvark Therapeutics and Acadia Pharmaceuticals raise concerns. The PWS market is valued at $600 million, but Soleno's $2.2 billion market cap seems inflated given its limited pipeline and looming competition. An analysis around Soleno Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Feb 26

We're Hopeful That Soleno Therapeutics (NASDAQ:SLNO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 08

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 10

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Summary Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. SLNO's robust cash position and recent equity raise ensure sufficient funding for DCCR's commercialization, reducing near-term dilution risks. Despite inherent biotech and market adoption risks, SLNO's favorable regulatory outlook and first-mover advantage in treating PWS hyperphagia justify a 'Strong Buy' rating. Read the full article on Seeking Alpha
Analysis Article • Mar 08

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, Soleno...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SLNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLNO's dividend payments have been increasing.

Dividend Yield vs Market

Soleno Therapeutics Dividend Yield vs Market
How does SLNO dividend yield compare to the market?
SegmentDividend Yield
Company (SLNO)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Biotechs)2.4%
Analyst forecast (SLNO) (up to 3 years)n/a

Notable Dividend: Unable to evaluate SLNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SLNO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLNO has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 19:10
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC